<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Raymond R Townsend, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1811981151"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>At the end of 2019, a novel coronavirus (ie, SARS-CoV-2) was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. By 2020, it led to a pandemic that has spread throughout most countries of the world. SARS-CoV-2 disease (COVID-19) primarily manifests as a lung infection with symptoms ranging from those of a mild upper respiratory infection to severe pneumonia, acute respiratory distress syndrome, and death. COVID-19 disproportionately affects patients with preexisting comorbidities, such as patients with various types of kidney disease. </p><p>With the widespread use of vaccinations, availability of antiviral therapy, and the emergence of less pathogenic variants of SARS-CoV-2, many strategies developed to mitigate the effect of COVID-19 on patients with kidney disease are no longer needed. However, it is possible that virulent cases of COVID-19 may surge again in the future. In addition, the response to the COVID-19 pandemic will inform the management of future outbreaks of severe respiratory disease in patients with kidney disease.</p><p>This topic will discuss issues related to COVID-19 and delivery of nephrology care in patients with acute kidney injury, glomerular disease, chronic kidney disease, and hypertension. Issues related to the care of patients who have end-stage kidney disease or who are candidates for or have a kidney transplant are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/130632.html" rel="external">"COVID-19: Issues related to end-stage kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation"</a>.)</p><p>Other important aspects of COVID-19 that may affect this population are discussed at length elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127533.html" rel="external">"COVID-19: Myocardial infarction and other coronary artery disease issues"</a>.)</p><p></p><p class="headingAnchor" id="H3752979725"><span class="h1">ACUTE KIDNEY INJURY</span><span class="headingEndMark"> — </span>Patients with suspected or confirmed COVID-19 may present with acute kidney injury (AKI) as part of their overall illness [<a href="#rid1">1-6</a>]. In a meta-analysis of approximately 13,000 mostly hospitalized patients, the incidence of AKI was 17 percent, although the range of AKI incidence in the included studies was broad (range 0.5 to 80 percent). Approximately 5 percent of patients required kidney replacement therapy (KRT) [<a href="#rid6">6</a>]. The incidence seems to vary by geographic location and proportion of critically ill patients included in each study. </p><p>While there are only limited data on temporal trends in the incidence of COVID-19-associated AKI, data suggest that rates of AKI in hospitalized patients declined over the duration of the pandemic although the reason for these trends was unclear [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H1878507871"><span class="h2">Clinical characteristics and histopathology</span><span class="headingEndMark"> — </span>Kidney disease among patients with COVID-19 can manifest as AKI, hematuria, or proteinuria, and portends a higher risk of mortality [<a href="#rid3">3,6,7,9-14</a>]. It remains unclear if AKI is largely due to hemodynamic changes and cytokine release or if the virus also leads to direct cytotoxicity. </p><p>The reported incidence of AKI among patients with COVID-19, especially those who are hospitalized, varies depending upon the severity of disease in the patients who are studied. In two large observational studies of over 5000 patients hospitalized with COVID-19, AKI was noted among 32 to 37 percent of patients [<a href="#rid4">4,7</a>]. Among patients with AKI, approximately one-half had mild disease (1.5- to 2-fold increase in serum creatinine), and the remaining had moderate or severe disease (more than doubling of creatinine). AKI requiring KRT was noted in 12 to 15 percent of patients. AKI was associated with requirement for mechanical ventilation and with a longer duration of hospitalization. Approximately one-half of the patients with AKI did not achieve complete recovery of their kidney function by hospital discharge [<a href="#rid7">7</a>]. Independent predictors of AKI included being older, Black American, or male; having obesity, diabetes, hypertension, cardiovascular disease, low baseline estimated glomerular filtration rate (eGFR), or higher interleukin-6 level; or requiring mechanical ventilation or vasopressor medications [<a href="#rid4">4,7,15</a>]. Similar findings were reported in another study [<a href="#rid13">13</a>].</p><p>In another study of over 3000 critically ill adults with COVID-19, 21 percent developed severe AKI requiring KRT within two weeks of admission to the intensive care unit (ICU) [<a href="#rid16">16</a>]. The 28-day mortality among such patients was approximately 50 percent; risk factors for death included older age, oliguria, and admission to a hospital with relatively limited ICU resources. Of those patients who survived to discharge, 34 percent were KRT-dependent at the time of discharge and more than one-half of those patients were still KRT-dependent by two months. It is unclear if the KRT dependence is related to the severity of critical illness or to the specific pathophysiology related to COVID-19. Long-term outcomes among patients requiring KRT in the setting of COVID-19 have not been studied.</p><p>One study compared the incidence of AKI among hospitalized patients with and without COVID-19 [<a href="#rid17">17</a>]. The incidence of AKI was higher among the 2600 patients who had COVID-19 compared with over 19,500 patients who were hospitalized for other reasons (31 versus 18 percent). This higher incidence of AKI could not be explained by differences in the traditional risk factors for AKI between the groups. COVID-19 remained associated with a higher rate of AKI despite controlling for demographic variables, comorbidities, frequency of hypotension, selected laboratory results (eg, complete blood count, baseline eGFR), and use of nephrotoxic medications, vasopressors, or mechanical ventilation (adjusted hazard ratio 1.40, 95% CI 1.29-1.53). Markers of inflammation, such as C-reactive protein and ferritin, appeared to be higher among patients who had COVID-19 compared with those who did not have COVID-19. However, the comparison of AKI between groups controlling for these inflammatory markers was not possible because only a few patients without COVID-19 had these checked during their hospitalization. In another study that compared outcomes among patients with similar baseline comorbidities who were hospitalized either for influenza or COVID-19, those with COVID-19 had AKI at a higher frequency (41 versus 29 percent) and greater severity (stage 3 AKI in 26 versus 6 percent) [<a href="#rid18">18</a>]. In addition, the 90-day mortality was higher among patients who had COVID-19 compared with those who had influenza (35 versus 9 percent). These findings raise questions about the various mechanisms of AKI among patients with COVID-19.</p><p>Kidney histopathology was examined in an autopsy series of 42 patients who died with COVID-19 [<a href="#rid19">19</a>]. Mean age of the patients included was 72 years (range, 39 to 97 years); 88 percent were over the age of 60 years. Comorbidities, such as hypertension (73 percent), diabetes (42 percent), coronary artery or cerebrovascular disease (32 percent), obesity (31 percent), and chronic kidney disease (29 percent) were common; only two patients had no underlying comorbidities. AKI (mostly stage 3) was noted among 31 of 33 patients. Most patients (62 percent) exhibited varying degrees of acute tubular necrosis (ATN), one had collapsing focal segmental glomerulosclerosis (FSGS), and many had sequelae of their medical comorbidities (eg, hypertensive nephrosclerosis). </p><p>ATN was also the predominant kidney pathologic finding in other studies [<a href="#rid3">3,20-25</a>]. Glomerular lesions were reported in a minority of patients with COVID-19. In addition, COVID-19 may also be associated with renal infarction [<a href="#rid26">26-31</a>]. (See <a class="local">'COVID-19 associated glomerular disease'</a> below and  <a class="medical medical_review" href="/z/d/html/7184.html" rel="external">"Renal infarction", section on 'Etiology and pathogenesis'</a>.)  </p><p>Whether SARS-CoV-2 causes a direct kidney infection remains controversial [<a href="#rid32">32</a>]. The presence of virus-like particles has been reported in the kidneys of patients with COVID-19 [<a href="#rid24">24,33</a>]. However, these may instead be endosomal subcellular structures (eg, clathrin-coated vesicles and multivesicular bodies) [<a href="#rid34">34</a>]. Ultrastructural in-situ hybridization used in some studies has confirmed presence of viral RNA [<a href="#rid35">35</a>] or viral proteins [<a href="#rid10">10</a>] in kidney tissue. Other studies have failed to demonstrate the presence of virus in the kidney [<a href="#rid19">19-21</a>].</p><p class="headingAnchor" id="H4010537099"><span class="h2">Evaluation of AKI in hospitalized patients</span><span class="headingEndMark"> — </span>In patients with suspected or confirmed COVID-19 who develop AKI, an emphasis should be placed on optimization of volume status to exclude and treat prerenal (functional) AKI while avoiding hypervolemia, which may worsen the patient's respiratory status.</p><p>The evaluation for other AKI etiologies should be undertaken in a manner similar to other critically ill patients with AKI. As an example, manual urine sediment examination should be performed, if appropriate, since urine samples are not considered to be highly infectious. </p><p class="headingAnchor" id="H1871577448"><span class="h2">Management of AKI in hospitalized patients</span></p><p class="headingAnchor" id="H332273832"><span class="h3">AKI requiring dialysis</span><span class="headingEndMark"> — </span>The indications for KRT for AKI remain the same regardless of the COVID-19 status of any given patient. </p><p>Several issues specific to KRT in patients with COVID-19 are discussed below:</p><p class="bulletIndent1"><span class="glyph">●</span>Circuit thrombosis during KRT occurs more frequently in patients with COVID-19 than in other patients [<a href="#rid36">36,37</a>]. In the absence of contraindications, patients with COVID-19 should receive anticoagulation during KRT. This can be in the form of regional anticoagulation using <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> or citrate, or systemic anticoagulation with unfractionated or low-molecular-weight heparin. Based on low quality data, <a class="drug drug_general" data-topicid="115978" href="/z/d/drug information/115978.html" rel="external">regional citrate anticoagulation</a> appears to be less effective among COVID-19 patients [<a href="#rid36">36,37</a>]; the reason for this is unclear. Additional details regarding anticoagulation for the hemodialysis procedure are presented separately, as is the issue of hypercoagulability in the setting of COVID-19. (See  <a class="medical medical_review" href="/z/d/html/1840.html" rel="external">"Anticoagulation for the hemodialysis procedure"</a> and  <a class="medical medical_review" href="/z/d/html/16855.html" rel="external">"Anticoagulation for continuous kidney replacement therapy"</a> and  <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on continuous kidney replacement therapy (CKRT), no special provisions or methods for disposal of the CKRT effluent are necessary. This is because neither presence of SARS-CoV-2 nor other similar viruses have been demonstrated in the effluent. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extracorporeal hemoperfusion devices for cytokine removal, such as Cytosorb, have had no clear role in management of sepsis prior to the COVID-19 pandemic. Due to lack of proven benefit, we do not use Cytosorb or other similar devices among critically ill COVID-19 patients with or without dialysis-requiring AKI. (See  <a class="medical medical_review" href="/z/d/html/1631.html" rel="external">"Investigational and ineffective pharmacologic therapies for sepsis", section on 'Cytokine and endotoxin inactivation or removal'</a>.)</p><p></p><p class="headingAnchor" id="H665057439"><span class="h3">AKI not requiring dialysis</span><span class="headingEndMark"> — </span>During a COVID-19 surge, patients who have AKI that is not dialysis-requiring should be managed with limited contact as much as possible. Physical examination and ultrasound evaluations should be coordinated with the primary/consulting teams to minimize contact, when possible. </p><p>Differences in management of AKI among patients with COVID-19 may include limited use of intravenous fluids. Most patients with COVID-19 characterized by pneumonia have variable degree of oxygen requirements and/or airway control. Fluid resuscitation goals are understandably conservative as per various acute respiratory distress syndrome criteria. Thus, fluid resuscitation should be individualized and based on trackable objective measures (eg, inferior vena cava collapse on ultrasound). </p><p class="headingAnchor" id="H1976641699"><span class="h2">Kidney function impairment after AKI</span><span class="headingEndMark"> — </span>The risk of developing chronic kidney disease (CKD) is high in patients with COVID-19-associated AKI. In an observational study from the United Kingdom, 16 percent of patients with AKI progressed to CKD by 90 days [<a href="#rid38">38</a>]. Similarly, in a study of United States veterans who survived at least 30 days after COVID-19 infection, the annual decrease in eGFR relative to controls not infected with COVID-19 was 3.3, 5.2, and 7.7 mL/min/1.73 m<sup>2</sup> in nonhospitalized patients, hospitalized patients, and patients requiring intensive care, respectively [<a href="#rid39">39</a>]. Corresponding decreases in eGFR were even more pronounced in patients who had COVID-19 associated AKI.</p><p class="headingAnchor" id="H1343514664"><span class="h1">GLOMERULAR DISEASE</span></p><p class="headingAnchor" id="H3731865109"><span class="h2">COVID-19 associated glomerular disease</span><span class="headingEndMark"> — </span>Glomerular lesions were reported in a minority of patients with COVID-19, with collapsing focal segmental glomerulosclerosis (FSGS), also called COVID-associated nephropathy (COVAN), being the most common [<a href="#rid20">20</a>]. Such patients present with nephrotic-range proteinuria and acute kidney injury (AKI) [<a href="#rid9">9,11,25,40-44</a>]. Similar to HIV-associated nephropathy, COVAN occurred exclusively in Black individuals, and a high proportion tested possessed high-risk APOL1 genotypes [<a href="#rid25">25,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/3080.html" rel="external">"Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)", section on 'APOL1 high-risk alleles'</a>.). </p><p>Thrombotic microangiopathy is another uncommon finding among patients who develop AKI and nephrotic-range proteinuria [<a href="#rid25">25</a>]. There are case reports of other glomerular diseases associated with COVID-19, including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [<a href="#rid45">45</a>], anti-glomerular basement membrane antibody disease [<a href="#rid46">46</a>], and IgA nephropathy [<a href="#rid47">47</a>].</p><p class="headingAnchor" id="H444042554"><span class="h2">COVID-19 vaccine-associated glomerular disease</span><span class="headingEndMark"> — </span>Both de novo glomerular disease and relapse of preexisting glomerular disease have been reported shortly after administration of COVID-19 messenger RNA (mRNA) vaccines (Moderna mRNA-1273 and Pfizer-BioNTech BNT162b2) [<a href="#rid48">48-60</a>]. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p>However, these are overall rare and a causal link with the COVID-19 vaccine is not firmly established. Our approach to COVID-19 vaccination among patients with glomerular disease is discussed below. (See <a class="local">'COVID-19 vaccination in patients with glomerular disease'</a> below.)</p><p>The following de novo glomerular diseases have been described following COVID-19 vaccination:</p><p class="bulletIndent1"><span class="glyph">●</span>IgA nephropathy [<a href="#rid48">48,49,61</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-neutrophilic cytoplasmic antibody (ANCA)-associated vasculitis [<a href="#rid48">48</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal change disease [<a href="#rid50">50-53,61,62</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-glomerular basement membrane (anti-GBM) nephritis [<a href="#rid49">49</a>]</p><p></p><p>In addition,<strong> a relapse</strong> of the following glomerular diseases has been reported following COVID-19 vaccination:</p><p class="bulletIndent1"><span class="glyph">●</span>IgA nephropathy [<a href="#rid54">54-56</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Minimal change disease [<a href="#rid57">57-59</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Primary membranous nephropathy [<a href="#rid60">60</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Complement-mediated thrombotic microangiopathy (C-TMA) [<a href="#rid63">63</a>]</p><p></p><p>Data delineating the risks of new onset or relapse of glomerular disease in the setting of COVID-19 vaccination are mixed. In a prospective cohort study of over 2000 patients with a history of biopsy-proven minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy, COVID-19 vaccination was not associated with an increase in glomerular disease activity as assessed by proteinuria and estimated glomerular filtration rate (eGFR) [<a href="#rid64">64</a>]. Furthermore, in two population-based observational studies, COVID-19 vaccination was not associated with a higher risk of incident [<a href="#rid65">65,66</a>] or recurrent [<a href="#rid66">66</a>] glomerular disease. However, in a Canadian cohort study of patients with preexisting glomerular disease, exposure to a second or third (but not first) COVID-19 vaccine dose was associated with a doubling of risk of relapse [<a href="#rid67">67</a>]. In the Canadian study, the increase in absolute risk of relapse associated with COVID-19 vaccination was small: 1 to 2 percent for ANCA-associated vasculitis, minimal change disease, membranous nephropathy, and FSGS, and 3 to 5 percent for IgA nephropathy and lupus nephritis.</p><p class="headingAnchor" id="H1417903516"><span class="h2">Modifications to the management of preexisting glomerular disease</span><span class="headingEndMark"> — </span>Patients with glomerular disease who are treated with immunosuppressive therapies may be at a heightened risk of infections (COVID-19 or other infections). However, there are no rigorous studies to guide pandemic-related modifications to the treatment of glomerular disease. We modify the immunosuppressive therapy in some patients with glomerular disease depending upon their risk of progression to end-stage kidney disease and the local transmission of COVID-19 [<a href="#rid68">68</a>].</p><p>Among patients who are at <strong>low risk of acquiring severe COVID-19</strong> because of limited community transmission and receipt of recommended COVID-19 vaccinations, we continue with their previously planned treatment for their glomerular disease. </p><p>Among patients who are <strong>at risk of acquiring severe COVID-19</strong> due to high regional transmission rates and other factors (eg, not appropriately vaccinated or inability to quarantine because of their occupation), we take the following approach: </p><p class="bulletIndent1"><span class="glyph">●</span>If the patient's glomerular disease is being treated with calcineurin inhibitors or <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>, no treatment modification is necessary (these drugs do not increase the risk of COVID-19). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, among other patients at risk of acquiring COVID-19, we modify our approach as follows: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are not yet on immunosuppressive therapy for their glomerular disease, we postpone treatment among the following groups: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with membranous nephropathy who have uncomplicated nephrotic syndrome and preserved eGFR </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients with IgA nephropathy who do not have features associated with a high risk of progression (eg, heavy proteinuria, impaired eGFR, or crescents on histopathology) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients who have glomerular diseases for which it is unclear that immunosuppressive therapy is beneficial (eg, infection-related glomerular disease)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who were initiated on immunosuppressive therapy before the pandemic and who are not yet in remission, an individual risk-benefit assessment is needed regarding continuation of such therapy. According to institutional policies, arrangements should be made for administration of necessary intravenous (IV) infusions at home rather than in an institutional infusion center. In addition, when possible, IV infusions should be changed to equivalent oral alternatives. As examples:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IV <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> could be changed to either oral cyclophosphamide or oral <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>IV pulse <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> could be changed to either oral high-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or oral methylprednisolone</p><p></p><p class="bulletIndent2">In patients who have glomerular diseases for which there is no widely accepted immunosuppressive strategy (eg, glucocorticoid-resistant FSGS), we avoid cytotoxic drugs (eg, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>), <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, and antimetabolites (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who were initiated on immunosuppressive therapy before the pandemic and who are already in remission, we lower the doses of their immunosuppressive medication to a minimum level that will maintain remission. Among patients who have been in remission for &gt;12 months, we favor immediate cessation of antimetabolites, such as <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, and avoidance of maintenance <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> infusions. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with glomerular disease who are receiving immunosuppressive therapy that includes antimetabolites and who have suspected or confirmed COVID-19, we discontinue antimetabolites for 7 to 10 days after symptom onset. In addition, among patients who are on long-term glucocorticoids and who require hospitalization for moderate to severe COVID-19, we also administer stress-dose glucocorticoids. Patients with nephrotic-range proteinuria who receive <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for treatment of COVID-19 should have an electrocardiogram performed to check the corrected QT interval. This is because patients with nephrotic syndrome can have a low ionized calcium. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with glomerular disease who are enrolled in research studies that entail having kidney biopsies purely for research purposes (rather than for clinical decision-making), such biopsies should be postponed or cancelled.</p><p></p><p class="headingAnchor" id="H3294628477"><span class="h2">COVID-19 vaccination in patients with glomerular disease</span><span class="headingEndMark"> — </span>Our approach to COVID-19 vaccination depends upon the timing of the onset or relapse of the glomerular disease (see <a class="local">'COVID-19 vaccine-associated glomerular disease'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glomerular disease not associated with vaccination </strong>–<strong> </strong>Among patients who develop glomerular disease (de novo or relapse) that is not temporally associated with a COVID-19 vaccination (ie, disease that occurs &gt;30 days after an administered vaccine), we encourage vaccinations as recommended for the general population. For patients whose immunosuppressive therapy consists of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> and for whom delaying therapy would be safe, we administer rituximab four to six weeks after COVID-19 vaccination. Other relevant pandemic-related treatment modifications are discussed above. (See <a class="local">'Modifications to the management of preexisting glomerular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glomerular disease associated with vaccination </strong>–<strong> </strong>Among patients who develop glomerular disease (de novo or relapse) that is temporally associated with a COVID-19 vaccination (ie, disease that occurs ≤30 days after an administered vaccine), it is possible that an additional dose of the vaccine will adversely impact their kidney function. The decision to proceed with additional vaccine doses for such patients should be based upon shared decision-making with the patient. The discussion of risks and benefits of vaccination should be individualized in context of the patient's type and severity of glomerular disease and whether or not they are in remission by the time of the next scheduled dose [<a href="#rid69">69</a>]. As examples, patients with minimal change disease who achieve remission or those with self-limited IgA nephropathy could receive an additional scheduled dose of vaccine. Conversely, patients with ANCA-associated vasculitis, C-TMA, or anti-GBM disease should likely not receive an additional dose.</p><p></p><p class="headingAnchor" id="H2824154764"><span class="h1">CHRONIC KIDNEY DISEASE AND HYPERTENSION</span><span class="headingEndMark"> — </span>Among patients with COVID-19, both chronic kidney disease (CKD) and hypertension are risk factors for more severe disease [<a href="#rid70">70-76</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of four studies and 1389 infected patients (including 273 patients with severe disease), the prevalence of underlying CKD was more frequent among those with severe disease (3.3 versus 0.4 percent; odds ratio 3.03, 95% CI 1.09-8.47) [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the same cohort of 1389 patients from these four studies, history of hypertension was more common among those who had severe, as compared with nonsevere, COVID-19 (15 versus 32 percent) [<a href="#rid73">73</a>]. Similarly, in a separate cohort of 1590 hospitalized patients in China, underlying hypertension was independently associated with severe COVID-19 (hazard ratio 1.58, 95% CI 1.07-2.32) [<a href="#rid70">70</a>]. While some studies conducted in the United States and Italy reveal broadly consistent findings [<a href="#rid71">71,72</a>], others suggest that hypertension is not an independent risk factor for severe COVID-19 [<a href="#rid74">74</a>].</p><p></p><p class="headingAnchor" id="H4251900404"><span class="h2">Renin angiotensin system inhibitors</span><span class="headingEndMark"> — </span>Patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should continue treatment with these agents (unless there is an indication for discontinuation such as hyperkalemia or hypotension). There is no evidence that stopping ACE inhibitors or ARBs reduces the severity of COVID-19 [<a href="#rid77">77-82</a>]. In addition, studies conducted prior to the COVID-19 pandemic suggest that discontinuing ACE inhibitors and ARBs in some patients may exacerbate underlying cardiovascular or kidney disease and lead to increased mortality [<a href="#rid83">83-85</a>]. This approach is supported by multiple guideline panels [<a href="#rid86">86-90</a>].</p><p>There was speculation that patients with COVID-19 who are receiving these agents may be at increased risk for adverse outcomes [<a href="#rid91">91,92</a>]. ACE2 is a receptor for SARS-CoV-2 [<a href="#rid93">93</a>] and some, but not all, evidence suggests that renin angiotensin system inhibitors may increase ACE2 levels [<a href="#rid94">94-97</a>]. In addition, patients with cardiovascular disease, hypertension, and diabetes (a disorder with a high prevalence of renin angiotensin system inhibitors-treated use) often have a more severe clinical course in the setting of infection with SARS-CoV-2.</p><p>However, there is no evidence to support discontinuation of renin angiotensin system inhibitors in patients diagnosed with COVID-19. The best data come from a trial of 740 hypertensive adults hospitalized for mild or moderate COVID-19 who were taking either an ACE inhibitor or ARB prior to hospitalization; patients were randomly assigned to continue or discontinue their ACE inhibitor or ARB for 30 days [<a href="#rid77">77</a>]. Compared with those assigned to discontinue therapy, those who continued taking an ACE inhibitor or ARB had statistically similar 30-day mortality (2.8 versus 2.7 percent), need for mechanical ventilation (7.7 versus 9.6 percent), shock requiring vasopressors (7.1 versus 8.4 percent), and median length-of-stay (five days in each group).</p><p>The conclusions of this trial are supported by multiple, large observational studies, most of which found no relationship between the use of ACE inhibitors or ARBs and severity of COVID-19 [<a href="#rid71">71,72,78-82,98-100</a>], although some suggested that these drugs may attenuate the severity of disease [<a href="#rid75">75,101-106</a>]. In addition, a meta-analysis of 14 trials that randomly assigned 1838 patients with COVID-19 to either renin angiotensin system inhibitor therapy (ie, continuing or initiating ACE inhibitor or ARB) or to no renin angiotensin system inhibitor therapy (ie, placebo or discontinuation of ACE inhibitor or ARB) reported similar rates of all-cause 30-day mortality in both treatment arms (7.2 percent versus 7.5 percent) [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H4082535810"><span class="h2">Dialysis access planning in advanced CKD</span><span class="headingEndMark"> — </span>During surges of COVID-19, patients with stage 4 or 5 CKD who are referred for dialysis access placement should undergo these procedures as planned (and not have their planned procedure deferred). </p><p>Although nonessential surgeries may be delayed during surges of COVID-19, guidance from the United States has clarified that placement of arteriovenous fistulas or grafts for hemodialysis and peritoneal dialysis catheters for peritoneal dialysis are <strong>essential</strong> procedures [<a href="#rid108">108,109</a>].</p><p class="headingAnchor" id="H2085260461"><span class="h1">MANAGING DIALYSIS DURING CRITICAL SHORTAGES</span><span class="headingEndMark"> — </span>During surges in cases of COVID-19 that result in unanticipated, critical shortages of health care providers and/or equipment, alterations in kidney replacement therapy (KRT) management may be necessary. These include some or all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with COVID-19 who require KRT should be colocalized on a floor or ICU, when possible. Colocalization within adjacent rooms can enable one dialysis nurse to simultaneously deliver dialysis to more than one patient. If a patient is in a negative-pressure isolation room, then one hemodialysis nurse will need to be dedicated for the care of that patient in a 1:1 nurse-to-patient ratio.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If possible, patients with suspected or confirmed COVID-19 who are not critically ill but who require KRT should be dialyzed in their isolation room rather than being transported to the inpatient dialysis unit.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even among patients who are hemodynamically stable and could tolerate intermittent hemodialysis, continuous kidney replacement therapy (CKRT) or prolonged intermittent kidney replacement therapy (PIKRT; also called sustained low-efficiency dialysis or SLED) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.covid19treatmentguidelines.nih.gov%2Fmanagement%2Fcritical-care-for-adults%2Facute-kidney-injury%2F&amp;token=LEK6bSG0c7EzaoqVYOQjIvfuzm7SkhZDk2nuaWnwUr6i8IMA8lBTblSjhq46%2BTqHDuxWLQiQ3uty2j5Uz9zhQJDuRNucBzn%2BhIF6NoGlHH9%2Ff2RoqGxv83C1fRPFoy%2Fd&amp;TOPIC_ID=127552" target="_blank">should be performed instead</a>, depending upon machine and staffing availability. This is because CKRT or PIKRT can be managed without 1:1 hemodialysis nursing support. This would potentially help minimize wastage of personal protective equipment and limit exposure among hemodialysis nurses.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CKRT machines can either be placed inside an isolation room as per standard practice or outside the room with the use of extended tubing. Placing the machine outside of the room minimizes the need for repeated entry to troubleshoot and manage the machine, and therefore reduces wastage of personal protective equipment. However, extended tubing is a scarce resource. In addition, use of extended tubing requires additional tubing connections and increases the likelihood that tubing will become disconnected. Extended tubing also decreases the sensitivity of pressure alarms to detect disconnection of the venous lines and potentially increases the risk of clotting due to the longer tubing length.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If CKRT capacity at an institution is overwhelmed, CKRT machines can be used to deliver prolonged intermittent treatments (eg, 10 hours rather than continuous) with higher flow rates (eg, 40 to 50 mL/kg/hour). Alternatively, the machine can be rotated between patients every 24 hours or whenever the circuit clots so that use of new filter sets is minimized. This will enable the CKRT machine to become available sooner for care of another patient after terminal cleaning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Institutions facing scarcity of replacement fluid for CKRT can lower the delivered dose to 15 mL/kg/hour from the standard 20 to 25 mL/kg/hour, especially among patients who are not hypercatabolic. One institution developed a real-time tracking system to account for and plan redistribution of scarce replacement fluid [<a href="#rid110">110</a>]. </p><p></p><p class="bulletIndent1">When supplies of commercially prepared replacement fluid are exhausted, institutional pharmacies may develop their own replacement fluid by mixing all of the following (in a sterile fashion) [<a href="#rid111">111</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1 L of 0.9 percent <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> with <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">potassium chloride</a> as needed</p><p class="bulletIndent2"><span class="glyph">•</span>1 L of 5 percent dextrose water with 150 mEq <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a></p><p class="bulletIndent2"><span class="glyph">•</span>1 L of 0.9 percent <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> with 1 g <a class="drug drug_general" data-topicid="10122" href="/z/d/drug information/10122.html" rel="external">magnesium chloride</a></p><p class="bulletIndent2"><span class="glyph">•</span>1 L of 0.9 percent <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> with 1 g <a class="drug drug_general" data-topicid="9186" href="/z/d/drug information/9186.html" rel="external">calcium chloride</a></p><p></p><p class="bulletIndent1">This will yield a 4 L solution containing 153 mEq/L sodium, 37.5 mEq/L bicarbonate, 2.6 mmol/L magnesium, 2.25 mmol/L calcium, and a variable amount of potassium.</p><p></p><p class="bulletIndent1">Other methods for preparation of dialysate solutions have been formulated at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fconsultqd.clevelandclinic.org%2Fan-in-house-solution-to-address-a-national-shortage-of-dialysate-video%2F&amp;token=gZAzK6%2BFuNvCayWoz%2F64yEQvxceZReOdg3bGQ62RNaaygebkmIQ8BX1TkEoao2iNtwD%2F0Q%2Bbhsv8XfLZFZFeiAl7TEa3stEmkyi85%2FOflyd3%2BikgpnDW08MFZHLdsLrI&amp;TOPIC_ID=127552" target="_blank">Cleveland Clinic</a> and Johns Hopkins Hospital [<a href="#rid112">112</a>] in the United States and Guy's and St Thomas' National Health Service Foundation Trust in the United Kingdom [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When available hemodialysis or CKRT machines are scarce, clinicians may need to consider treatment of AKI with peritoneal dialysis [<a href="#rid114">114-119</a>]. Important considerations include: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with AKI who are treated with peritoneal dialysis have similar rates of all-cause mortality, kidney function recovery, and infectious complications compared with patients treated with other modalities. (See  <a class="medical medical_review" href="/z/d/html/1884.html" rel="external">"Use of peritoneal dialysis (PD) for the treatment of acute kidney injury (AKI) in adults", section on 'Outcomes with PD for AKI'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peritoneal dialysis requires relatively less equipment, infrastructure, and resources relative to other forms of KRT. Nurses and clinicians can be trained expeditiously to provide peritoneal dialysis. (See  <a class="medical medical_review" href="/z/d/html/1884.html" rel="external">"Use of peritoneal dialysis (PD) for the treatment of acute kidney injury (AKI) in adults", section on 'Outcomes with PD for AKI'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Peritoneal dialysis can increase intra-abdominal pressure, interfere with respiratory mechanics [<a href="#rid120">120</a>], and may theoretically worsen respiratory failure, particularly among mechanically ventilated patients. However, it can be used among mechanically ventilated patients when other options such as intermittent hemodialysis and CKRT are not available. Performing peritoneal dialysis in a mechanically ventilated patient who requires a prone position may be challenging although one case report found it to be feasible and safe [<a href="#rid121">121</a>]. (See  <a class="medical medical_review" href="/z/d/html/1884.html" rel="external">"Use of peritoneal dialysis (PD) for the treatment of acute kidney injury (AKI) in adults", section on 'Complications of PD for AKI'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When peritoneal dialysis is used for management of AKI in patients with COVID-19, automated peritoneal dialysis with a cycler should be used, if available. This minimizes the contact between health care personnel and the patient. (See  <a class="medical medical_review" href="/z/d/html/1884.html" rel="external">"Use of peritoneal dialysis (PD) for the treatment of acute kidney injury (AKI) in adults", section on 'Selecting PD modalities for AKI'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar to disposal of peritoneal dialysis effluent for patients with end-stage kidney disease, there is a range of opinions for safe disposal of the effluent in the setting of AKI. Data suggesting that peritoneal dialysis effluent is infectious are lacking [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/130632.html" rel="external">"COVID-19: Issues related to end-stage kidney disease", section on 'Inpatients during a COVID-19 surge'</a>.)</p><p></p><p class="headingAnchor" id="H1331017041"><span class="h1">INFECTION CONTROL PRACTICES</span><span class="headingEndMark"> — </span>Infection control practices specific to the care of patients with kidney disease requiring dialysis are presented in the preceding discussions.</p><p>The general approach to infection control in the health care setting, in the home, and in non-hospital institutional settings, as well as the approach to discontinuation of COVID-19 precautions and return-to-work for health care personnel, are presented in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p class="headingAnchor" id="H1488135923"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H745839606"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a>)  </p><p></p><p class="headingAnchor" id="H3027045719"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 and kidney disease</strong> – SARS-CoV-2 disease (COVID-19) disproportionately affects patients with various types of kidney disease. Pandemic-era strategies developed to mitigate the effect of COVID-19 on patients with kidney disease will inform the management of future outbreaks of severe respiratory disease.(See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney replacement therapy during critical shortages</strong> – During surges in cases of COVID-19 that result in unanticipated, critical shortages of health care providers and/or equipment, alterations in kidney replacement therapy (KRT) management may be necessary. These include some or all of the following (see <a class="local">'Managing dialysis during critical shortages'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with COVID-19 should be colocalized on a floor or intensive care unit (ICU), when possible. Colocalization within adjacent rooms can enable one dialysis nurse to simultaneously deliver dialysis for more than one patient. If a patient is in a negative-pressure isolation room, then one hemodialysis nurse will need to be dedicated for the care of that patient in a 1:1 nurse-to-patient ratio.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When possible, patients with suspected or confirmed COVID-19 who are not critically ill should be dialyzed in their own isolation room rather than being transported to the inpatient dialysis unit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Continuous kidney replacement therapy (CKRT) is preferred among critically ill patients in the ICU who have end-stage kidney disease (ESKD) or acute kidney injury (AKI). Even among patients who are hemodynamically stable and who could tolerate intermittent hemodialysis, CKRT or prolonged intermittent kidney replacement therapy (PIKRT), also called sustained low-efficiency dialysis (SLED), should be performed instead, depending upon machine and staffing availability. This is because CKRT or PIKRT can be managed without 1:1 hemodialysis support. This would potentially help minimize wastage of personal protective equipment and limit exposure among hemodialysis nurses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If CKRT capacity at an institution is overwhelmed, CKRT machines can be used to deliver prolonged intermittent treatments (eg, 10 hours rather than continuous) with higher flow rates (eg, 40 to 50 mL/kg/hour). This will enable the CKRT machine to become available sooner for care of another patient after terminal cleaning.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When available hemodialysis or CKRT machines are scarce, clinicians may need to consider treatment of AKI with peritoneal dialysis. (See  <a class="medical medical_review" href="/z/d/html/1884.html" rel="external">"Use of peritoneal dialysis (PD) for the treatment of acute kidney injury (AKI) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>AKI in hospitalized patients</strong> – In patients with severe COVID-19 who develop AKI, an emphasis should be placed on optimization of volume status to exclude and treat prerenal (functional) AKI while avoiding hypervolemia, which may worsen the patient's respiratory status. During surges of COVID-19, patients who have AKI that is not dialysis-requiring should be managed with limited contact as much as possible. Physical examination and ultrasound evaluations should be coordinated with the primary/consulting teams to minimize contact, when possible. (See <a class="local">'Evaluation of AKI in hospitalized patients'</a> above and <a class="local">'AKI not requiring dialysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 and glomerular disease</strong> – Both COVID-19 and vaccination against COVID-19 may be associated with the development of glomerular disease. In addition, due to the heightened risk of infection among immunosuppressed patients, those who have preexisting glomerular disease and who are at high risk of severe COVID-19 may require modifications to their management plan. (See <a class="local">'Modifications to the management of preexisting glomerular disease'</a> above and <a class="local">'COVID-19 vaccination in patients with glomerular disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 and renin angiotensin system inhibitors</strong> – Patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should continue treatment with these agents (unless there is an indication for discontinuation such as hyperkalemia or hypotension). There is no evidence that stopping ACE inhibitors or ARBs reduces the severity of COVID-19. (See <a class="local">'Renin angiotensin system inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Access planning</strong> – During surges of COVID-19, patients with stage 4 or 5 CKD who are referred for dialysis access placement should undergo these procedures as planned (and not have their planned procedure deferred). (See <a class="local">'Dialysis access planning in advanced CKD'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8:475.</a></li><li><a class="nounderline abstract_t">Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.</a></li><li><a class="nounderline abstract_t">Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020; 97:829.</a></li><li><a class="nounderline abstract_t">Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 2020; 98:209.</a></li><li><a class="nounderline abstract_t">Ng JJ, Luo Y, Phua K, Choong AMTL. Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): A meta-analysis. J Infect 2020; 81:647.</a></li><li><a class="nounderline abstract_t">Robbins-Juarez SY, Qian L, King KL, et al. Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney Int Rep 2020; 5:1149.</a></li><li><a class="nounderline abstract_t">Bowe B, Cai M, Xie Y, et al. Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clin J Am Soc Nephrol 2020; 16:14.</a></li><li><a class="nounderline abstract_t">Charytan DM, Parnia S, Khatri M, et al. Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City. Kidney Int Rep 2021; 6:916.</a></li><li><a class="nounderline abstract_t">Larsen CP, Bourne TD, Wilson JD, et al. Collapsing Glomerulopathy in a Patient With COVID-19. Kidney Int Rep 2020; 5:935.</a></li><li><a class="nounderline abstract_t">Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 2020; 98:219.</a></li><li><a class="nounderline abstract_t">Kissling S, Rotman S, Gerber C, et al. Collapsing glomerulopathy in a COVID-19 patient. Kidney Int 2020; 98:228.</a></li><li><a class="nounderline abstract_t">Pei G, Zhang Z, Peng J, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol 2020; 31:1157.</a></li><li><a class="nounderline abstract_t">Chan L, Chaudhary K, Saha A, et al. AKI in Hospitalized Patients with COVID-19. J Am Soc Nephrol 2021; 32:151.</a></li><li><a class="nounderline abstract_t">Karras A, Livrozet M, Lazareth H, et al. Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Single-Center Study. Clin J Am Soc Nephrol 2021; 16:514.</a></li><li><a class="nounderline abstract_t">Xia P, Wen Y, Duan Y, et al. Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort. J Am Soc Nephrol 2020; 31:2205.</a></li><li><a class="nounderline abstract_t">Gupta S, Coca SG, Chan L, et al. AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19. J Am Soc Nephrol 2021; 32:161.</a></li><li><a class="nounderline abstract_t">Moledina DG, Simonov M, Yamamoto Y, et al. The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. Am J Kidney Dis 2021; 77:490.</a></li><li><a class="nounderline abstract_t">Birkelo BC, Parr SK, Perkins AM, et al. Comparison of COVID-19 versus influenza on the incidence, features, and recovery from acute kidney injury in hospitalized United States Veterans. Kidney Int 2021; 100:894.</a></li><li><a class="nounderline abstract_t">Santoriello D, Khairallah P, Bomback AS, et al. Postmortem Kidney Pathology Findings in Patients with COVID-19. J Am Soc Nephrol 2020; 31:2158.</a></li><li><a class="nounderline abstract_t">May RM, Cassol C, Hannoudi A, et al. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int 2021; 100:1303.</a></li><li><a class="nounderline abstract_t">Sharma P, Uppal NN, Wanchoo R, et al. COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings. J Am Soc Nephrol 2020; 31:1948.</a></li><li><a class="nounderline abstract_t">Kudose S, Batal I, Santoriello D, et al. Kidney Biopsy Findings in Patients with COVID-19. J Am Soc Nephrol 2020; 31:1959.</a></li><li><a class="nounderline abstract_t">Golmai P, Larsen CP, DeVita MV, et al. Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19. J Am Soc Nephrol 2020; 31:1944.</a></li><li><a class="nounderline abstract_t">Werion A, Belkhir L, Perrot M, et al. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int 2020; 98:1296.</a></li><li><a class="nounderline abstract_t">Akilesh S, Nast CC, Yamashita M, et al. Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria. Am J Kidney Dis 2021; 77:82.</a></li><li><a class="nounderline abstract_t">Post A, den Deurwaarder ESG, Bakker SJL, et al. Kidney Infarction in Patients With COVID-19. Am J Kidney Dis 2020; 76:431.</a></li><li><a class="nounderline abstract_t">Añazco PH, Balta FM, Córdova-Cueva L. Bilateral renal infarction in a patient with severe COVID-19 infection. J Bras Nefrol 2021; 43:127.</a></li><li><a class="nounderline abstract_t">Guillet H, Gallet R, Pham V, et al. Clinical spectrum of ischaemic arterial diseases associated with COVID-19: a series of four illustrative cases. Eur Heart J Case Rep 2021; 5:ytaa488.</a></li><li><a class="nounderline abstract_t">Topel C, Yıldırım C, Yavaş MA, et al. Aortic floating thrombi with lower limb ischemia and renal infarct in COVID-19: A remote thromboembolic complication. Turk Kardiyol Dern Ars 2021; 49:233.</a></li><li><a class="nounderline abstract_t">Murray NP, Fuentealba C, Reyes E, Salazar A. Renal infarction associated with asymptomatic Covid-19 infection. Hematol Transfus Cell Ther 2021; 43:353.</a></li><li><a class="nounderline abstract_t">Webb C, Davidson B, Jones ESW, et al. COVID-19-Associated Graft Loss From Renal Infarction in a Kidney Transplant Recipient. Kidney Int Rep 2021; 6:1166.</a></li><li><a class="nounderline abstract_t">Lite C, Ahmed SSSJ, Juliet M, Freddy AJ. SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host. Pathog Dis 2021; 79.</a></li><li><a class="nounderline abstract_t">Farkash EA, Wilson AM, Jentzen JM. Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2. J Am Soc Nephrol 2020; 31:1683.</a></li><li><a class="nounderline abstract_t">Goldsmith CS, Miller SE, Martines RB, et al. Electron microscopy of SARS-CoV-2: a challenging task. Lancet 2020; 395:e99.</a></li><li><a class="nounderline abstract_t">Braun F, Lütgehetmann M, Pfefferle S, et al. SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 2020; 396:597.</a></li><li><a class="nounderline abstract_t">Shankaranarayanan D, Muthukumar T, Barbar T, et al. Anticoagulation Strategies and Filter Life in COVID-19 Patients Receiving Continuous Renal Replacement Therapy: A Single-Center Experience. Clin J Am Soc Nephrol 2020; 16:124.</a></li><li><a class="nounderline abstract_t">Yuang Wen, Jason R. LeDoux, Muner Mohamed, et al. Dialysis Filter Life, Anticoagulation, and Inflammation in COVID-19 and Acute Kidney Injury. Kidney360 1.</a></li><li><a class="nounderline abstract_t">Lumlertgul N, Pirondini L, Cooney E, et al. Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study. Ann Intensive Care 2021; 11:123.</a></li><li><a class="nounderline abstract_t">Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney Outcomes in Long COVID. J Am Soc Nephrol 2021; 32:2851.</a></li><li><a class="nounderline abstract_t">Peleg Y, Kudose S, D'Agati V, et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep 2020; 5:940.</a></li><li><a class="nounderline abstract_t">Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 2020; 16:565.</a></li><li><a class="nounderline abstract_t">Sharma Y, Nasr SH, Larsen CP, et al. COVID-19-Associated Collapsing Focal Segmental Glomerulosclerosis: A Report of 2 Cases. Kidney Med 2020; 2:493.</a></li><li><a class="nounderline abstract_t">Nasr SH, Kopp JB. COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity. Kidney Int Rep 2020; 5:759.</a></li><li><a class="nounderline abstract_t">Shetty AA, Tawhari I, Safar-Boueri L, et al. COVID-19-Associated Glomerular Disease. J Am Soc Nephrol 2021; 32:33.</a></li><li><a class="nounderline abstract_t">Uppal NN, Kello N, Shah HH, et al. De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19. Kidney Int Rep 2020; 5:2079.</a></li><li><a class="nounderline abstract_t">Prendecki M, Clarke C, Cairns T, et al. Anti-glomerular basement membrane disease during the COVID-19 pandemic. Kidney Int 2020; 98:780.</a></li><li><a class="nounderline abstract_t">Huang Y, Li XJ, Li YQ, et al. Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report. BMC Nephrol 2020; 21:504.</a></li><li><a class="nounderline abstract_t">Anderegg MA, Liu M, Saganas C, et al. De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int 2021; 100:474.</a></li><li><a class="nounderline abstract_t">Tan HZ, Tan RY, Choo JCJ, et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int 2021; 100:469.</a></li><li><a class="nounderline abstract_t">Lebedev L, Sapojnikov M, Wechsler A, et al. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78:142.</a></li><li><a class="nounderline abstract_t">Maas RJ, Gianotten S, van der Meijden WAG. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78:312.</a></li><li><a class="nounderline abstract_t">D'Agati VD, Kudose S, Bomback AS, et al. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int 2021; 100:461.</a></li><li><a class="nounderline abstract_t">Holzworth A, Couchot P, Cruz-Knight W, Brucculeri M. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine. Kidney Int 2021; 100:463.</a></li><li><a class="nounderline abstract_t">Perrin P, Bassand X, Benotmane I, Bouvier N. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int 2021; 100:466.</a></li><li><a class="nounderline abstract_t">Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int 2021; 99:1487.</a></li><li><a class="nounderline abstract_t">Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int 2021; 100:238.</a></li><li><a class="nounderline abstract_t">Komaba H, Wada T, Fukagawa M. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021; 78:469.</a></li><li><a class="nounderline abstract_t">Kervella D, Jacquemont L, Chapelet-Debout A, et al. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine. Kidney Int 2021; 100:457.</a></li><li><a class="nounderline abstract_t">Schwotzer N, Kissling S, Fakhouri F. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine". Kidney Int 2021; 100:458.</a></li><li><a class="nounderline abstract_t">Aydın MF, Yıldız A, Oruç A, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int 2021; 100:464.</a></li><li><a class="nounderline abstract_t">Waldman M, Sinaii N, Lerma EV, et al. COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry. Kidney360 2023; 4:349.</a></li><li><a class="nounderline abstract_t">Mancianti N, Guarnieri A, Tripodi S, et al. Minimal change disease following vaccination for SARS-CoV-2. J Nephrol 2021; 34:1039.</a></li><li><a class="nounderline abstract_t">Ville S, Le Bot S, Chapelet-Debout A, et al. Atypical HUS relapse triggered by COVID-19. Kidney Int 2021; 99:267.</a></li><li><a class="nounderline abstract_t">Wang CS, Glenn DA, Helmuth M, et al. Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study. Am J Kidney Dis 2024; 83:37.</a></li><li><a class="nounderline abstract_t">Diebold M, Locher E, Boide P, et al. Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased. Kidney Int 2022; 102:1409.</a></li><li><a class="nounderline abstract_t">Cheng FWT, Wong CKH, Qin SX, et al. Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines. Nephrol Dial Transplant 2023; 38:129.</a></li><li><a class="nounderline abstract_t">Canney M, Atiquzzaman M, Cunningham AM, et al. A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination. J Am Soc Nephrol 2022; 33:2247.</a></li><li><a class="nounderline abstract_t">Bomback AS, Canetta PA, Ahn W, et al. How COVID-19 Has Changed the Management of Glomerular Diseases. Clin J Am Soc Nephrol 2020; 15:876.</a></li><li><a class="nounderline abstract_t">Bomback AS, Kudose S, D'Agati VD. De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far? Am J Kidney Dis 2021; 78:477.</a></li><li><a class="nounderline abstract_t">Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med 2020; 382:2441.</a></li><li><a class="nounderline abstract_t">Mancia G, Rea F, Ludergnani M, et al. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med 2020; 382:2431.</a></li><li><a class="nounderline abstract_t">Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol 2020; 52:1193.</a></li><li><a class="nounderline abstract_t">Iaccarino G, Grassi G, Borghi C, et al. Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. Hypertension 2020; 76:366.</a></li><li><a class="nounderline abstract_t">Pan W, Zhang J, Wang M, et al. Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients. Hypertension 2020; 76:732.</a></li><li><a class="nounderline abstract_t">Yang D, Xiao Y, Chen J, et al. COVID-19 and chronic renal disease: clinical characteristics and prognosis. QJM 2020; 113:799.</a></li><li><a class="nounderline abstract_t">Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA 2021; 325:254.</a></li><li><a class="nounderline abstract_t">Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol 2020; 5:825.</a></li><li><a class="nounderline abstract_t">Vaduganathan M, Vardeny O, Michel T, et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med 2020; 382:1653.</a></li><li><a class="nounderline abstract_t">Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J 2020; 41:1801.</a></li><li><a class="nounderline abstract_t">de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet 2020; 395:1705.</a></li><li><a class="nounderline abstract_t">Fosbøl EL, Butt JH, Østergaard L, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA 2020; 324:168.</a></li><li><a class="nounderline abstract_t">Qiao Y, Shin JI, Chen TK, et al. Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate. JAMA Intern Med 2020; 180:718.</a></li><li><a class="nounderline abstract_t">Pflugfelder PW, Baird MG, Tonkon MJ, et al. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol 1993; 22:1557.</a></li><li><a class="nounderline abstract_t">Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet 2019; 393:61.</a></li><li class="breakAll">Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician (Accessed on March 18, 2020).</li><li class="breakAll">European Society of Hypertension. ESH Statement on COVID-19. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/ (Accessed on March 18, 2020).</li><li class="breakAll">International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/ (Accessed on March 18, 2020).</li><li class="breakAll">Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (Accessed on March 18, 2020).</li><li class="breakAll">Hypertension Canada. Hypertension Canada’s Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf (Accessed on March 18, 2020).</li><li><a class="nounderline abstract_t">Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020; 17:259.</a></li><li><a class="nounderline abstract_t">Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8:e21.</a></li><li><a class="nounderline abstract_t">Wan Y, Shang J, Graham R, et al. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 2020; 94.</a></li><li><a class="nounderline abstract_t">Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605.</a></li><li><a class="nounderline abstract_t">Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004; 43:970.</a></li><li><a class="nounderline abstract_t">Soler MJ, Ye M, Wysocki J, et al. Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. Am J Physiol Renal Physiol 2009; 296:F398.</a></li><li><a class="nounderline abstract_t">Wysocki J, Lores E, Ye M, et al. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. J Am Soc Nephrol 2020; 31:1941.</a></li><li><a class="nounderline abstract_t">Mackey K, King VJ, Gurley S, et al. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review. Ann Intern Med 2020; 173:195.</a></li><li><a class="nounderline abstract_t">Flacco ME, Acuti Martellucci C, Bravi F, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart 2020; 106:1519.</a></li><li><a class="nounderline abstract_t">Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart 2020; 106:1503.</a></li><li><a class="nounderline abstract_t">Zhou F, Liu YM, Xie J, et al. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. Hypertension 2020; 76:e15.</a></li><li><a class="nounderline abstract_t">Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; 11:875.</a></li><li><a class="nounderline abstract_t">Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol 2018; 314:L17.</a></li><li><a class="nounderline abstract_t">Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020; 126:1671.</a></li><li><a class="nounderline abstract_t">Yang G, Tan Z, Zhou L, et al. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Hypertension 2020; 76:51.</a></li><li><a class="nounderline abstract_t">Guo X, Zhu Y, Hong Y. Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis. Hypertension 2020; 76:e13.</a></li><li><a class="nounderline abstract_t">Gnanenthiran SR, Borghi C, Burger D, et al. Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. J Am Heart Assoc 2022; 11:e026143.</a></li><li><a class="nounderline abstract_t">Khalid U, Ilham MA, Szabo L, et al. Arterio-venous fistula surgery can be safely delivered in the COVID-19 pandemic era. J Vasc Access 2022; 23:330.</a></li><li><a class="nounderline abstract_t">Basile C, Lomonte C, Combe C, et al. A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic. J Nephrol 2021; 34:365.</a></li><li><a class="nounderline abstract_t">Stevens JS, Toma K, Tanzi-Pfeifer S, et al. Dashboards to Facilitate Nephrology Disaster Planning in the COVID-19 Era. Kidney Int Rep 2020; 5:1298.</a></li><li><a class="nounderline abstract_t">Burgner A, Ikizler TA, Dwyer JP. COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis. Clin J Am Soc Nephrol 2020; 15:720.</a></li><li><a class="nounderline abstract_t">Singhala M, Bell R, Cenci B, et al. Emergency Production and Collection of Dialysate for CVVHD During the COVID-19 Pandemic. Kidney Int Rep 2021; 6:2200.</a></li><li><a class="nounderline abstract_t">Lumlertgul N, Tunstell P, Watts C, et al. In-House Production of Dialysis Solutions to Overcome Challenges During the Coronavirus Disease 2019 Pandemic. Kidney Int Rep 2021; 6:200.</a></li><li><a class="nounderline abstract_t">Sourial MY, Sourial MH, Dalsan R, et al. Urgent Peritoneal Dialysis in Patients With COVID-19 and Acute Kidney Injury: A Single-Center Experience in a Time of Crisis in the United States. Am J Kidney Dis 2020; 76:401.</a></li><li><a class="nounderline abstract_t">El Shamy O, Vassalotti JA, Sharma S, et al. Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent. Kidney Int 2020; 98:782.</a></li><li><a class="nounderline abstract_t">Parapiboon W, Ponce D, Cullis B. Acute peritoneal dialysis in COVID-19. Perit Dial Int 2020; 40:359.</a></li><li><a class="nounderline abstract_t">El Shamy O, Patel N, Abdelbaset MH, et al. Acute Start Peritoneal Dialysis during the COVID-19 Pandemic: Outcomes and Experiences. J Am Soc Nephrol 2020; 31:1680.</a></li><li><a class="nounderline abstract_t">Goldfarb DS, Benstein JA, Zhdanova O, et al. Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients. Clin J Am Soc Nephrol 2020; 15:880.</a></li><li><a class="nounderline abstract_t">Nina J. Caplin, Olga Zhdanova, Manish Tandon, Nathan Thompson. Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City. Kidney360 2020; 1.</a></li><li><a class="nounderline abstract_t">Almeida CP, Ponce D, de Marchi AC, Balbi AL. Effect of peritoneal dialysis on respiratory mechanics in acute kidney injury patients. Perit Dial Int 2014; 34:544.</a></li><li><a class="nounderline abstract_t">Klisnick A, Souweine B, Filaire M, et al. Peritoneal dialysis in a patient receiving mechanical ventilation in prone position. Perit Dial Int 1998; 18:536.</a></li></ol></div><div id="topicVersionRevision">Topic 127552 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32105632" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217556" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247631" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Kidney disease is associated with in-hospital death of patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416116" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Acute kidney injury in patients hospitalized with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32389782" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32775814" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33199414" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33558853" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32292867" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Collapsing Glomerulopathy in a Patient With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32327202" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32471639" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Collapsing glomerulopathy in a COVID-19 patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345702" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32883700" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : AKI in Hospitalized Patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661756" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Proteinuria and Clinical Outcomes in Hospitalized COVID-19 Patients: A Retrospective Single-Center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32826326" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33067383" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33422598" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34111501" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of COVID-19 versus influenza on the incidence, features, and recovery from acute kidney injury in hospitalized United States Veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32727719" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Postmortem Kidney Pathology Findings in Patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352311" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32660970" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : COVID-19-Associated Kidney Injury: A Case Series of Kidney Biopsy Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32680910" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Kidney Biopsy Findings in Patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32675304" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Histopathologic and Ultrastructural Findings in Postmortem Kidney Biopsy Material in 12 Patients with AKI and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32791255" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33045255" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multicenter Clinicopathologic Correlation of Kidney Biopsies Performed in COVID-19 Patients Presenting With Acute Kidney Injury or Proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479921" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kidney Infarction in Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33460428" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bilateral renal infarction in a patient with severe COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33542975" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical spectrum of ischaemic arterial diseases associated with COVID-19: a series of four illustrative cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33847272" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aortic floating thrombi with lower limb ischemia and renal infarct in COVID-19: A remote thromboembolic complication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34027306" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Renal infarction associated with asymptomatic Covid-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33553853" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : COVID-19-Associated Graft Loss From Renal Infarction in a Kidney Transplant Recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33469663" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : SARS-CoV-2/human interactome reveals ACE2 locus crosstalk with the immune regulatory network in the host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32371536" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ultrastructural Evidence for Direct Renal Infection with SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442529" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Electron microscopy of SARS-CoV-2: a challenging task.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32818439" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : SARS-CoV-2 renal tropism associates with acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32943397" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Anticoagulation Strategies and Filter Life in COVID-19 Patients Receiving Continuous Renal Replacement Therapy: A Single-Center Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Dialysis Filter Life, Anticoagulation, and Inflammation in COVID-19 and Acute Kidney Injury</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34357478" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Acute kidney injury prevalence, progression and long-term outcomes in critically ill patients with COVID-19: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34470828" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Kidney Outcomes in Long COVID.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32346659" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32753739" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32775990" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : COVID-19-Associated Collapsing Focal Segmental Glomerulosclerosis: A Report of 2 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32368701" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33214201" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : COVID-19-Associated Glomerular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32839744" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32599088" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anti-glomerular basement membrane disease during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33234164" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34087251" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : De novo vasculitis after mRNA-1273 (Moderna) vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34033857" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Is COVID-19 vaccination unmasking glomerulonephritis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33839200" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33992727" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000278" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048824" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34087252" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33771584" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33932458" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023417" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33964312" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34052236" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33992674" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36996301" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : COVID-19 Vaccination and New Onset Glomerular Disease: Results from the IRocGN2 International Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34143368" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Minimal change disease following vaccination for SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33188793" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Atypical HUS relapse triggered by COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37657635" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Association of COVID-19 Versus COVID-19 Vaccination With Kidney Function and Disease Activity in Primary Glomerular Disease: A Report of the Cure Glomerulonephropathy Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36096267" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36367015" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk of glomerular diseases, proteinuria and hematuria following mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36332971" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32332048" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : How COVID-19 Has Changed the Management of Glomerular Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34182049" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217650" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356628" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356627" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222883" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32564693" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654555" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensin-aldosterone System Inhibitors on the Prognosis of COVID-19 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32840579" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : COVID-19 and chronic renal disease: clinical characteristics and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464336" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32324209" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32227760" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196087" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416785" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32558877" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32150237" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227822" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429050" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429050" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429050" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429050" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429050" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429050" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139904" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : COVID-19 and the cardiovascular system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171062" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31996437" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15897343" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15007027" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19004932" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32669323" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32422062" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32611676" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32737124" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32493070" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007097" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28935640" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302265" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32348166" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32458694" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36000426" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33356795" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Arterio-venous fistula surgery can be safely delivered in the COVID-19 pandemic era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33683675" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32775829" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Dashboards to Facilitate Nephrology Disaster Planning in the COVID-19 Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32245780" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34127951" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Emergency Production and Collection of Dialysate for CVVHD During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33195882" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : In-House Production of Dialysis Solutions to Overcome Challenges During the Coronavirus Disease 2019 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32534129" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Urgent Peritoneal Dialysis in Patients With COVID-19 and Acute Kidney Injury: A Single-Center Experience in a Time of Crisis in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32592816" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32552550" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Acute peritoneal dialysis in COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32546597" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Acute Start Peritoneal Dialysis during the COVID-19 Pandemic: Outcomes and Experiences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345750" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25074997" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Effect of peritoneal dialysis on respiratory mechanics in acute kidney injury patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848637" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Peritoneal dialysis in a patient receiving mechanical ventilation in prone position.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
